Related Experiment Video

Updated: Jul 5, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.5K

Mild Cognitive Impairment Progression and Alzheimer's Disease Risk: A Comprehensive Analysis of 3553 Cases over 203

Nevra Öksüz1, Reza Ghouri1, Bahar Taşdelen2

  • 1Department of Neurology, School of Medicine, Mersin University, Mersin 33110, Turkey.

Journal of Clinical Medicine
|January 23, 2024
PubMed

Insights

Mild cognitive impairment (MCI) significantly progresses to dementia, with Alzheimer's disease (AD) cases advancing faster. This study highlights key cognitive changes and effective assessment tools for MCI progression.

Area of Science:

  • Neurology
  • Gerontology
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) represents a transitional stage between normal aging and dementia.
  • Understanding MCI progression is crucial for early intervention and differentiating subtypes.

Purpose of the Study:

  • To track the long-term progression of MCI in a longitudinal cohort.
  • To compare MCI progression between Alzheimer's disease (AD) and non-AD subtypes.
  • To identify factors influencing MCI progression and effective diagnostic tools.

Main Methods:

  • Longitudinal study of 140 participants with MCI, categorized into AD and non-AD subtypes.
  • Regular neuropsychological assessments using tools like the Mini-Mental State Examination (MMSE) and Global Deterioration Scale (GDS).
  • Analysis of progression rates to clinical dementia stages.

Main Results:

  • An overall MCI to dementia progression rate of 92.8% was observed, with an annual rate of 15.7%.
  • All Lewy body dementia/Parkinson's disease (LBD/PDD) and frontotemporal dementia (FTD) cases progressed, unlike some vascular dementia (VaD) and AD cases.
  • MCI cases associated with AD showed a faster progression rate (53.9%) compared to non-AD subtypes (35.5%).
  • MMSE, GDS, and calculation tests were identified as most effective for evaluating MCI.

Conclusions:

  • MCI demonstrates significant long-term cognitive changes, with varying progression rates based on dementia subtype.
  • Alzheimer's disease-related MCI progresses more rapidly than other subtypes.
  • Findings support the development of personalized interventions and highlight effective assessment tools for MCI.
Keywords:
Alzheimer’s diseaseNon-AD MCIcognitive functiondementiadisease progressionhippocampal atrophymild cognitive impairment

More Related Videos

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment08:43

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

7.9K
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

32.4K

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
115
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
112
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
126